fda tirzepatide shortage resolved oct 2 2024 Zepbound ends, impacts patients, compounding pharmacies 2024 Ends With Lilly's Landmark

Information on this website is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment.

How Jurni GLP supports you, day by day From quick logs to meaningful progress insights

According to the STEP clinical trials referenced in NICE TA875, patients treated with Wegovy achieved substantial weight loss, typically in the range of 10-15% of initial body weight over 68 weeks of treatment when combined with lifestyle interventions

Tirzepatides unique dual-action mechanism targets both GLP-1 and GIP receptors, enhancing its efficacy in appetite suppression and weight loss compared to medications that target only one pathway

For example, you may need to make medication adjustments or lifestyle changes to support your goal